BAUSCH HEALTH AMERICAS, INC.
🇺🇸United States
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
Phase 4
Completed
- Conditions
- Colon Cleansing
- Interventions
- Drug: Oral sodium phosphate solution
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 2154
- Registration Number
- NCT01427296
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
- First Posted Date
- 2011-06-16
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT01374490
Compassionate Use Study of Methylnaltrexone
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01368562
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01367509
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Open-Label Treatment Extension of Protocol MNTX 302
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT01367613
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Open-Label Treatment Extension of Protocol MNTX 301
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01367600
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Tarrytown, New York, United States
Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus
Phase 2
Completed
- Conditions
- Postoperative Ileus
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01367548
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01367496
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01367483
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01367587
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
© Copyright 2025. All Rights Reserved by MedPath